Enfortumab Vedotin and Pembrolizumab - A New Perspective on Urothelial Cancer

N Engl J Med. 2024 Mar 7;390(10):944-946. doi: 10.1056/NEJMe2400311.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal* / adverse effects
  • Antibodies, Monoclonal* / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Carcinoma, Transitional Cell* / drug therapy
  • Humans
  • Urinary Bladder Neoplasms / drug therapy
  • Urologic Neoplasms* / drug therapy

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • enfortumab vedotin
  • pembrolizumab